Antiviral Drugs - Morocco

Morocco

The Antiviral Drugs market in Morocco is predicted to generate a revenue of US$24.67m in 2024.
It is expected to exhibit an annual growth rate of 2.08% from 2024 to 2029, resulting in a market volume of US$27.34m by 2029.
In terms of global comparison, United States is projected to generate the highest revenue of US$30,640.00m in 2024.
Morocco's pharmaceutical industry is experiencing a surge in demand for antiviral drugs due to the country's increasing prevalence of viral diseases.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Antiviral Drugs market in Morocco is experiencing significant growth in recent years.

Customer preferences: The demand for antiviral drugs in Morocco is driven by the increasing prevalence of viral diseases, including HIV, hepatitis, and influenza. Customers are also seeking more effective treatments with fewer side effects, leading to a shift towards newer antiviral drugs.

Trends in the market: One of the major trends in the Antiviral Drugs market in Morocco is the increasing availability of generic antiviral drugs. This has led to increased competition and lower prices, making treatment more affordable for patients. Another trend is the development of new antiviral drugs that offer improved efficacy and safety profiles. These drugs are expected to drive growth in the market in the coming years.

Local special circumstances: Morocco has a high prevalence of viral diseases, particularly hepatitis and HIV. This has led to increased demand for antiviral drugs in the country. Additionally, the government has implemented several initiatives to improve access to healthcare, including the provision of free antiretroviral therapy for HIV patients. These initiatives are expected to drive growth in the Antiviral Drugs market in Morocco.

Underlying macroeconomic factors: Morocco has a growing economy, with a focus on developing its healthcare sector. The government has allocated significant resources towards improving healthcare infrastructure and increasing access to healthcare services. Additionally, the country has a large pharmaceutical industry, which is expected to benefit from the growth of the Antiviral Drugs market. Overall, these macroeconomic factors are expected to support the growth of the Antiviral Drugs market in Morocco in the coming years.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.